GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®. The clinical results have shown that their product has significantly helped patients with Dravet syndrome treat and reduce their seizures associated with the disease.
Epidiolex is available in 10 mg/kg per day and 20 mg/kg per day doses. Both of the concentrations were effective in reduces the occurrence of seizures in patients of years 2-18. GW Pharma utilized a sample size of 199 patients broken up by EPIDIOLEX 20 mg/kg/day (n=67), EPIDIOLEX 10 mg/kg/day (n=67) or placebo (n=65).
Recently, GW Pharma’s product Epidiolex was approved by the FDA to be sold in the United States as a pharmaceutical grade product option for patients throughout the country. This was the first time the FDA had approved a cannabinoid derived medication to be prescribed by medical professionals in the US.
Research has shown that CBD oil has shown to be effective in treating a number of different medical conditions including anxiety, inflammation, seizures, depression, heart disease, diabetes, and pain relief.
“The positive outcome in this second trial of EPIDIOLEX in patients with Dravet syndrome further reinforces the effectiveness of this newly available medicine in this particularly difficult to treat, childhood-onset epilepsy,” stated Ian Miller, M.D., Director, Epilepsy and Neurophysiology Program at Nicklaus Children’s Hospital in Miami, Florida.